Nonacog alfa - Pfizer
Alternative Names: BeneFIX; Blood-coagulation-factor-IX-synthetic-human; Coagulation Factor IX (Recombinant) - Pfizer; Factor-IX-Genetics-InstituteLatest Information Update: 05 Nov 2023
At a glance
- Originator University of Oxford; Washington Research Foundation
- Developer Grifols; Pfizer
- Class Antihaemorrhagics; Blood coagulation factors
- Mechanism of Action Blood coagulation factor replacements; Factor IX stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Haemophilia B
Most Recent Events
- 28 Apr 2018 No recent reports of development identified for phase-I development in Haemophilia-B in China (IV, Infusion)
- 05 Aug 2016 Takeda and Pfizer terminates its commercialisation agreement for nonacog alfa in Japan
- 08 Mar 2016 Updated efficacy data from a phase III trial in Haemophilia B released by Pfizer